They also recognize the value of their team and recently granted stock options to new employees. With $167.5 million and a strategy focused on INO-3107, they look poised to tap the potential of DNA-based drugs.īut at Inovio, it’s not all science and trials. The green light from the FDA and the possibility of suspending the Phase 3 trial have accelerated Inovio’s commercialization plans, putting it on the map for potential investors. market, promising a new frontier in healthcare. What is truly exciting is that INO-3107 could be the first DNA drug to reach the U.S.
This breakthrough therapy designation paves the way for Inovio to file a Biologics License Application (BLA) more quickly than anticipated, skipping the previously planned Phase 3 trial. Its flagship product, INO-3107, has just received FDA clearance as a potential breakthrough for the treatment of recurrent respiratory papillomatosis (RRP), a rare disease caused by HPV. Inovio Pharmaceuticals (NASDAQ: INO) is a biotech company that is making waves with its innovative DNA-based drugs.
